BEGIN YOUR JOURNEY TOWARDS PREVENTING CRYPTOGENIC STROKE

If you’ve had a stroke due to an unknown cause, learn how you may be able to prevent another with the Amplatzer™ PFO Occluder.

Current selected region:
UNITED STATES
I'm a patient healthcare professionals
Skip to main content

After cryptogenic stroke, make prevention the priority

Key visual

By closing a PFO associated with a cryptogenic stroke with the Amplatzer™ PFO Occluder, you can significantly reduce your patient’s risk of stroke recurrence.

Find out more

Preventing a recurring stroke Close The Patent Foramen Ovale (PFO)

~25%
About one quarter of ischemic strokes are cryptogenic¹
50%
Nearly 50% of young adults with cryptogenic stroke have a PFO²
97%
Patients experienced up to a 97% risk reduction of recurring stroke after PFO closure³

Find out how PFO closure might help your patients

Abbott created the PFO occlusion category, and the Amplatzer™ PFO Occluder has sustained leadership over decades of use and was the first device supported by positive trial results.

Treatment options
Amplatzer™ PFO occluder
Occluder stroke risk ref3 2x

Reduce their risk of stroke recurrence

The Amplatzer™ PFO Occluder was studied in the RESPECT Trial in the US and Canada. The trial enrolled 980 patients, between the ages of 18 to 60, who were diagnosed with a PFO and a cryptogenic stroke. Patients were randomly assigned to either receive the Amplatzer™ PFO Occluder plus blood-thinning medication, or blood-thinning medication alone. The patients were assessed at 30 days, six months, one year and yearly thereafter. The RESPECT Trial was designed to evaluate whether PFO closure with the Amplatzer™ PFO Occluder plus blood-thinning medication was more effective in reducing the risk of another ischemic stroke compared with the sole use of blood-thinning medication. Over a median follow-up period of 5.9 years, the rate of recurrent ischemic stroke was 45% lower with PFO closure compared to medical management exclusively.⁴

In the CLOSE Trial, 663 patients received either the Amplatzer™ PFO Occluder or another approved PFO occluder. This trial showed a 97% stroke risk reduction in patients who underwent PFO closure plus antiplatelet therapy compared to patients who received antiplatelets only.³

About the Amplatzer™ PFO Occluder

Hear from a fellow medical professional

We can do better in stroke prevention by using them (Amplatzer PFO) in the appropriate patient.”

— Jeffrey Saver, MD, UCLA Comprehensive Stroke Center

The turning point for cryptogenic stroke treatment

Three extensive clinical studies have confirmed the superiority of PFO closure to medical management in reducing the risk of stroke recurrence. ³⁻⁵

Learn more
References
  1. Saver, J.L. Cryptogenic Stroke. NEJM 2016; 374: 2065-74.
  2. Mojadidi, M.K. et al, Cryptogenic Stroke and Patent Foramen Foramen Ovale. Journal of the American College of Cardiology, Vol 71, No. 9, 2018 1035-42.
  3. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377: 1011-21
  4. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377: 1022-32.
  5. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377: 1033-42.
MAT-2002586 v2.0 | Item approved for OUS use only